David A Weaver

Title: The Innovations of David A. Weaver: Advancements in Lung Cancer Diagnosis

Introduction: David A. Weaver, an accomplished inventor based in Perrysburg, Ohio, has made significant contributions to the field of oncology through his innovative research and inventions. With a total of four patents, Weaver has focused primarily on methods for diagnosing and monitoring non-small cell lung cancer (NSCLC) and bronchogenic carcinoma.

Latest Patents: One of Weaver's latest inventions is a method for selecting treatment for non-small cell lung cancer using gene expression profiles. This groundbreaking patent identifies and quantifies changes in gene expression associated with NSCLC by analyzing tissue from both normal lung and diseased lung, providing valuable diagnostic markers to monitor disease progression and response to treatment. Another significant patent involves the quantitative measurement of gene expression to identify individuals at risk for bronchogenic carcinoma, utilizing reverse transcription-polymerase chain reaction (RT-PCR) to measure the expression of multiple target genes simultaneously.

Career Highlights: David A. Weaver has worked with notable institutions such as the University of Toledo and the Medical College of Ohio. His work at these institutions has not only advanced cancer research but also enriched his expertise in molecular biology and gene expression profiling.

Collaborations: Throughout his career, Weaver has collaborated with key figures in the field, including coworkers like James C. Willey and Erin Crawford. These partnerships have facilitated innovative research efforts and fostered a collaborative environment conducive to scientific discovery.

Conclusion: David A. Weaver's contributions to cancer research through his patents highlight the importance of innovation in medical science. His methods for diagnosing and monitoring lung cancer exemplify how inventive thinking can lead to improved patient outcomes and advance the field of oncology.